PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33803354-5	2021	The MAPK14-ATF2-axis represents a collateral pathway ensuring persisting ERK-activation in the presence of sorafenib-mediated RAF-inhibition.	Sorafenib	107-116	activating transcription factor 2	Homo sapiens	11-15	
33803354-7	2021	We found combined overexpression of MAPK14 and ATF2 in human HCC cells, tissues and in sorafenib resistant cell lines.	Sorafenib	87-96	activating transcription factor 2	Homo sapiens	47-51	
33021963-4	2020	miR-216a-3p overexpression significantly increases the sorafenib sensitivity of HCC cells by suppressing MAPK14 expression and reducing the subsequent activation of the MEK/ERK and ATF2 signaling pathways.	Sorafenib	55-64	activating transcription factor 2	Homo sapiens	181-185	
29693700-0	2018	Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.	Sorafenib	80-89	activating transcription factor 2	Homo sapiens	10-43	
29693700-10	2018	The mRNA and protein expression levels of ATF2 in the sorafenib or siRNA-ATF2 groups was significantly reduced when compared with control group.	Sorafenib	54-63	activating transcription factor 2	Homo sapiens	42-46	
29693700-11	2018	The phosphorylation of ATF2 was also reduced following sorafenib treatment or ATF2 silence.	Sorafenib	55-64	activating transcription factor 2	Homo sapiens	23-27	
29693700-14	2018	It is of note that siRNA-ATF2 treatment promoted the anticancer activity of sorafenib in Huh-7 cells.	Sorafenib	76-85	activating transcription factor 2	Homo sapiens	25-29	
29693700-16	2018	Combined siRNA-ATF2 and sorafenib treatment had a greater anticancer effect compared with sorafenib or ATF2 silencing alone.	Sorafenib	90-99	activating transcription factor 2	Homo sapiens	15-19